<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Biotech on FinanClub</title>
    <link>https://finan.club/tags/biotech/</link>
    <description>Recent content in Biotech on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Mon, 12 Feb 2024 09:13:29 +0000</lastBuildDate><atom:link href="https://finan.club/tags/biotech/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>ARDX</title>
      <link>https://finan.club/us/ardx/</link>
      <pubDate>Mon, 12 Feb 2024 09:13:29 +0000</pubDate>
      
      <guid>https://finan.club/us/ardx/</guid>
      <description>score:-68
Chances: The average of price targets set by Wall Street analysts indicates a potential upside of 34.8% in Ardelyx (ARDX). Ardelyx (ARDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).</description>
    </item>
    
    <item>
      <title>IMGN</title>
      <link>https://finan.club/us/imgn/</link>
      <pubDate>Fri, 09 Feb 2024 09:02:41 +0000</pubDate>
      
      <guid>https://finan.club/us/imgn/</guid>
      <description>score:135
Chances: ImmunoGen has seen solid earnings estimate revision activity over the past two months,ImmunoGen (IMGN) might move higher on growing optimism about its earnings prospects ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Risks: AbbVie Inc. announced its plans to acquire ImmunoGen in an all-cash transaction valued at roughly $10.</description>
    </item>
    
    <item>
      <title>MRNA</title>
      <link>https://finan.club/us/mrna/</link>
      <pubDate>Wed, 17 Jan 2024 09:04:41 +0000</pubDate>
      
      <guid>https://finan.club/us/mrna/</guid>
      <description>score:-55
Chances: Moderna&amp;rsquo;s product pipeline includes a wide range of modalities, such as prophylactic vaccines, cancer vaccines, and localized regenerative therapeutics, providing opportunities for significant future growth. The company&amp;rsquo;s focus on intratumoral immuno-oncology and systemic intracellular therapeutics reflects a strong commitment to addressing complex medical challenges with innovative solutions.</description>
    </item>
    
  </channel>
</rss>
